Neurology

Significant opportunities exist for the development of new drugs for relapsing remitting multiple sclerosis.

Human Vaccines Project seeks to decode the human immune system to facilitate accelerated development of diagnostics, vaccines and therapies for major global diseases.

Fingolimod was previously approved to treat relapsing multiple sclerosis as a once-daily disease-modifying therapy.

Disrupting the circadian rhythm exacerbate multiple sclerosis symptoms.

Patients with multiple sclerosis who eat healthy could reduce their risk of severe disability by 20%.

Increasing myelin production by targeting oligodendrocytes shows promise as a treatment for multiple sclerosis.

Treating aging patients with immunomodulatory drugs further increases the risk of infections.

The presence of a nerve protein in the blood may indicate the development of new T1 and T2 lesions resulting from multiple sclerosis.

A small number of multiple sclerosis cases following vaccinations affected compliance with vaccination recommendations.

Top articles of the week from The American Journal of Pharmacy Benefits.

Cell structure may allow immune cells to attack myelin in multiple sclerosis.

Another study suggests gut bacteria has an important role in triggering multiple sclerosis.

Targeting specific transportation system across the damaged blood-brain barrier could halt MS disease progression.

Multiple sclerosis researchers actively seek new agents than can promote repair and remyelination.

Experimental drug found to reduce inflammation and promote remyelination in patients with relapsing-remitting multiple sclerosis.

The brain may stop the process of repairing myelin due to a blood clotting protein.

MRI brain scans on children at high risk of multiple sclerosis may indicate earlier diagnoses and treatments.

Exercise found to be one of the most important approaches for self-managing the consequences of multiple sclerosis.

Ozanimod may slow multiple sclerosis progression more than first-line therapy.

Research questions whether reducing sodium intake could reduce the risk of developing multiple sclerosis.

Fingolimod shows 82% efficacy reducing the annualized multiple sclerosis relapse rate.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

Combination therapy found to reverse multiple sclerosis in mice models.

A look at last week's top stories in the world of pharmacy.